UoOxford Confidence in Concept 2013
Lead Research Organisation:
University of Oxford
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
Organisations
- University of Oxford (Lead Research Organisation)
- Penlon (Collaboration)
- PUBLIC HEALTH ENGLAND (Collaboration)
- Biotest AG (Collaboration)
- National Institute for Biological Standards and Control (NIBSC) (Collaboration)
- University of Dundee (Collaboration)
- UNIVERSITY OF OXFORD (Collaboration)
- EVOTEC (Collaboration)
- Radboud University Nijmegen Medical Center (Collaboration)
- University of Auckland (Collaboration)
- Massachusetts General Hospital (Collaboration)
- Sealife Pharma (Collaboration)
- Children's Hospital Oakland Research Institute (CHORI) (Collaboration)
People |
ORCID iD |
Publications
Meier JC
(2017)
Selective Targeting of Bromodomains of the Bromodomain-PHD Fingers Family Impairs Osteoclast Differentiation.
in ACS chemical biology
Calvopiña K
(2016)
Sideromimic Modification of Lactivicin Dramatically Increases Potency against Extensively Drug-Resistant Stenotrophomonas maltophilia Clinical Isolates.
in Antimicrobial agents and chemotherapy
Giustacchini A
(2017)
Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia.
in Nature medicine
Salimraj R
(2016)
Structural and Biochemical Characterization of Rm3, a Subclass B3 Metallo-ß-Lactamase Identified from a Functional Metagenomic Study
in Antimicrobial Agents and Chemotherapy
Salimraj R
(2016)
Structural and Biochemical Characterization of Rm3, a Subclass B3 Metallo-ß-Lactamase Identified from a Functional Metagenomic Study.
in Antimicrobial agents and chemotherapy
Lennox BR
(2019)
Study of immunotherapy in antibody positive psychosis: feasibility and acceptability (SINAPPS1).
in Journal of neurology, neurosurgery, and psychiatry
Wills QF
(2015)
Studying epigenomics in single cells: what is feasible and what can we learn?
in Epigenomics
Al-Diwani A
(2017)
Synaptic and Neuronal Autoantibody-Associated Psychiatric Syndromes: Controversies and Hypotheses.
in Frontiers in psychiatry
| Description | -VaxCelerate: Development of a T Cell-Based Vaccine for Q Fever |
| Amount | $163,000 (USD) |
| Organisation | Massachusetts General Hospital |
| Sector | Hospitals |
| Country | United States |
| Start | 08/2018 |
| End | 07/2019 |
| Description | A novel bivalent vaccine to prevent both Salmonella Typhi and Paratyphi infections: preclinical proof of concept |
| Amount | £55,000 (GBP) |
| Organisation | BactiVac Network |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 08/2019 |
| Description | ARUK pilot grant |
| Amount | £46,738 (GBP) |
| Funding ID | ARUK-PPG2017A-19 |
| Organisation | Versus Arthritis |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2017 |
| End | 05/2018 |
| Description | Centres of Excellence in Neurodegeneration |
| Amount | £250,683 (GBP) |
| Funding ID | 1509HM013/NF2 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2016 |
| End | 04/2018 |
| Description | Clinical development of a new vaccine for rapid response against Plague: GMP production and phase I trial |
| Amount | £3,000,000 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Confidence in Concept 3 |
| Amount | £17,849 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2016 |
| End | 08/2016 |
| Description | Confidence in concept Oxford |
| Amount | £45,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2017 |
| End | 06/2018 |
| Description | Development Pathway Funding Scheme |
| Amount | £546,210 (GBP) |
| Funding ID | MR/R006423/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2018 |
| End | 04/2021 |
| Description | Development of a novel vaccine to protect against Q fever epidemics: late stage preclinical formulation and progression to clinical trial |
| Amount | £1,000,000 (GBP) |
| Funding ID | 971619 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 08/2020 |
| Description | Developmental Pathway Funding Scheme |
| Amount | £2,187,000 (GBP) |
| Organisation | MRC Biomedical Catalyst Developmental Pathway Funding Scheme (DPFS) |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 04/2017 |
| End | 04/2021 |
| Description | ENABLE IMI |
| Amount | £439,422 (GBP) |
| Organisation | European Commission |
| Department | Innovative Medicines Initiative (IMI) |
| Sector | Public |
| Country | Belgium |
| Start | 09/2016 |
| Description | IOI |
| Amount | £100,000,000 (GBP) |
| Organisation | INEOS |
| Sector | Private |
| Country | United Kingdom |
| Start | |
| Description | Jenner Institute Investigator |
| Amount | £3,000 (GBP) |
| Organisation | University of Oxford |
| Department | Jenner Institute |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2019 |
| End | 12/2019 |
| Description | Jenner Institute Investigator |
| Amount | £3,000 (GBP) |
| Organisation | University of Oxford |
| Department | Jenner Institute |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2018 |
| End | 12/2018 |
| Description | Jenner Institute Investigator |
| Amount | £3,000 (GBP) |
| Organisation | University of Oxford |
| Department | Jenner Institute |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2015 |
| End | 12/2015 |
| Description | Jenner Institute Investigator |
| Amount | £3,000 (GBP) |
| Organisation | University of Oxford |
| Department | Jenner Institute |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2016 |
| End | 12/2016 |
| Description | Jenner Institute Investigator |
| Amount | £3,000 (GBP) |
| Organisation | University of Oxford |
| Department | Jenner Institute |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2017 |
| End | 12/2017 |
| Description | Jenner Investigator award |
| Amount | £2,000 (GBP) |
| Organisation | University of Oxford |
| Department | Jenner Institute |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 04/2019 |
| End | 03/2020 |
| Description | MND Association PhD Studentship |
| Amount | £96,252 (GBP) |
| Organisation | Motor Neurone Disease Association (MND) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 10/2016 |
| End | 09/2019 |
| Description | MRC CRI: The Oxford Single Cell Biology Consortium (co-investigator) |
| Amount | £4,975,434 (GBP) |
| Funding ID | MR/M00919X/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2015 |
| End | 04/2016 |
| Description | MRC DPFS |
| Amount | £2,711,781 (GBP) |
| Funding ID | MR/N019067/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2016 |
| End | 07/2020 |
| Description | MRC Discovery Award (co-investigator) |
| Amount | £1,000,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2016 |
| End | 04/2019 |
| Description | MRC Discovery Award - Identification and characterisation of cellular targets for genome editing of foetal haematopoietic stem/progenitor cells |
| Amount | £56,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2016 |
| End | 08/2017 |
| Description | MRC Proximity to discovery Industry Engagement Fund |
| Amount | £10,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2016 |
| End | 07/2016 |
| Description | New vaccines for global epidemics (Plague) |
| Amount | £100,000 (GBP) |
| Funding ID | 972228 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2016 |
| End | 09/2017 |
| Description | Novel antibody discovery in psychosis |
| Amount | £2,200,000 (GBP) |
| Organisation | Johnson & Johnson |
| Sector | Private |
| Country | United States |
| Start | |
| Description | Programme Grant Renewal |
| Amount | £1,700,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2016 |
| End | 04/2021 |
| Description | Proof of Concept |
| Amount | £111,924 (GBP) |
| Funding ID | 641317 |
| Organisation | European Research Council (ERC) |
| Sector | Public |
| Country | Belgium |
| Start | 03/2015 |
| End | 09/2016 |
| Description | Rosetrees Trust |
| Amount | £40,000 (GBP) |
| Organisation | Rosetrees Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2015 |
| End | 01/2017 |
| Description | SBRI |
| Amount | £360,000 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2016 |
| End | 09/2017 |
| Description | SBRI Vaccines against outbreak diseases |
| Amount | £3,000,000 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 10/2017 |
| End | 09/2020 |
| Description | SINAPPS-2 study |
| Amount | $300,000 (USD) |
| Organisation | Stanley Medical Research Institute (SMRI) |
| Sector | Charity/Non Profit |
| Country | Global |
| Start | |
| Description | Senior Investigator Award |
| Amount | £2,262,504 (GBP) |
| Funding ID | 104633/Z/14/Z |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2015 |
| End | 02/2021 |
| Description | Stanley Medical Research Institute treatment trials |
| Amount | $284,176 (USD) |
| Organisation | Stanley Medical Research Institute (SMRI) |
| Sector | Charity/Non Profit |
| Country | Global |
| Start | 07/2015 |
| End | 07/2016 |
| Description | UCSF |
| Amount | £36,000 (GBP) |
| Organisation | University of Oxford |
| Department | Oxford University Innovation |
| Sector | Private |
| Country | United Kingdom |
| Start | 11/2017 |
| End | 02/2019 |
| Description | Wellcome Trust ISSF |
| Amount | £150,135 (GBP) |
| Organisation | Wellcome Trust |
| Department | Wellcome Trust Institutional Strategic Support Fund |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2014 |
| End | 11/2017 |
| Description | vaccines for global epidemics - preclinical (Q fever) |
| Amount | £100,000 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2017 |
| End | 04/2018 |
| Title | Bayesian modelling of slow wave activity saturation |
| Description | SWAS is an electrophysiological phenomenon that occurs under general anaesthesia. Our functional magnetic resonance imaging data suggest that at SWAS in an individual loses perception of incoming external stimuli. We developed Bayesian methods to characterise slow wave activity saturation (SWAS) in electroencephalography (EEG) data in off-line and real-time modes as there is significant translational potential for SWAS-based depth of anaesthesia monitoring. |
| Type Of Material | Model of mechanisms or symptoms - human |
| Provided To Others? | No |
| Impact | This is the first development step towards adaptive, smart and individualised depth of anaesthesia monitoring based on SWAS. This monitor will potentially help anaesthetists deliver the optimum anaesthetic dose and reduce the deleterious consequences of under- and over-anaesthesia. We have filed a patent based on perception loss at SWAS that includes this Bayesian modelling. |
| Title | Biosignatures in brain tissue |
| Description | A novel method for differentiation of neuropsychiatric conditions based on the identification and modelling of signature patterns of microstructural change in the organisation of the cerebral cortex |
| Type Of Material | Model of mechanisms or symptoms - human |
| Provided To Others? | No |
| Impact | This method forms part of a patent which has been filed. |
| Title | Evaluation of in vitro antigen expression as a correlate of immunogenicity |
| Description | We have developed an in vitro assay intending to measure antigen expression achieved in cell lines after infection by viral vectored vaccine candidate, in order to replace some of the mouse immunogenicity studies. The number of vaccine candidate developed with modifications, for example of the promoter, signal sequences or vector backbone, is high, and implies that a lot of mice are used to compare the immunogenicity of these vaccines. We believe that this approach could be refined, by measuring the level of antigen expressed by each vaccine in mice and human cells. We hypothesise that the level of antigen expression is a main driver of immunogenicity (albeit not the only one). Therefore screening of new vectors can be performed in cells rather than in animal experiment, in particular in the case of comparing vector backbones, as this is more likely to influence immunogenicity in a specie-specific manner. Therefore screening in cells, in particular human cells rather than mouse is highly relevant. |
| Type Of Material | Model of mechanisms or symptoms - in vitro |
| Year Produced | 2015 |
| Provided To Others? | Yes |
| Impact | In our group this technology has allowed understanding of mechanisms driving antigen expression fro viral vaccine candidates, as well as selection of vectors with optimal antigen expression for further testing in in vivo experiments. |
| Title | IMPACT |
| Description | Rapid calculation of ion mobility collision cross sections |
| Type Of Material | Improvements to research infrastructure |
| Year Produced | 2015 |
| Provided To Others? | Yes |
| Impact | Published and downloaded |
| Title | NMR assay |
| Description | This project has enabled the development and optimisation of a novel NMR screening protocol for the assessment of plasma protein binding, which simultaneously gives an assessment both of the level and location of binding. This information is particularly valuable for the design of new antibacterial agents with lowered plasma protein binding, a characteristic widely believed to enhance the level of bioactivity. Moreover, it has permitted initial work to demonstrate the viability of a wholly novel drug delivery system. |
| Type Of Material | Technology assay or reagent |
| Provided To Others? | No |
| Impact | Facilitated understanding a key aspect of antibacterial drug discovery |
| Title | PULSAR |
| Description | Correlates unfolding with stability |
| Type Of Material | Improvements to research infrastructure |
| Year Produced | 2015 |
| Provided To Others? | Yes |
| Impact | Published and downloaded |
| Title | adenovirus-based vaccine technology |
| Description | . Our adenovirus-based vaccine technology is the first vaccine to our knowledge that uses human cells as the expression system for an outer membrane protein from extracellular bacteria, using the adjuvant properties of a viral vector. This is innovative as bacterial outer membrane proteins might not be expected to fold properly or to undergo the correct post-translational modifications in a mammalian cell, and our findings with a MenB antigen are innovative and promising. |
| Type Of Material | Technology assay or reagent |
| Provided To Others? | No |
| Impact | Progress to GMP for phase I study |
| Description | A novel vaccine for broad protection against meningococcal disease: selection of the optimal product composition for a phase I clinical trial |
| Organisation | Children's Hospital Oakland Research Institute (CHORI) |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | We established a fruitful and successful collaboration with P. Beernink at CHORI, Oakland, USA. We have provided expertise in vaccine development |
| Collaborator Contribution | Our partner has provided sequences for proteins to be included in a vaccine candidate |
| Impact | Potential for patents and publications |
| Start Year | 2014 |
| Description | Antibacterial bioassays |
| Organisation | Sealife Pharma |
| Country | Austria |
| Sector | Private |
| PI Contribution | Supply of new chemical entities |
| Collaborator Contribution | Supply of antibacterial bioassays |
| Impact | Data not finalised yet |
| Start Year | 2014 |
| Description | BP project |
| Organisation | National Institute for Biological Standards and Control (NIBSC) |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Concept, design and production of novel vaccine candidates against BP |
| Collaborator Contribution | Expertise in measuring immune response to BP vaccines, and efficacy in models |
| Impact | Application for joint D.Phil studentship |
| Start Year | 2016 |
| Description | Biotest |
| Organisation | Biotest AG |
| Country | Germany |
| Sector | Private |
| PI Contribution | Agreement with Biotest for the production of IVIG and placebo for the trial |
| Collaborator Contribution | Agreement with Biotest for the production of IVIG and placebo for the trial |
| Impact | Agreement with Biotest for the production of IVIG and placebo for the trial |
| Start Year | 2022 |
| Description | Clinical Interpretation of SWAS |
| Organisation | University of Auckland |
| Department | Faculty of Medical and Health Sciences |
| Country | New Zealand |
| Sector | Academic/University |
| PI Contribution | We identified slow wave activity saturation (SWAS), generated the Bayesian model to determine whether an individual had achieved SWAS and applied this to our experimental data. |
| Collaborator Contribution | Professor Jamie Sleigh, a world leader in electroencephalography under anaesthesia research, provided clinical EEG datasets acquired under surgical anaesthesia that allowed us to test and refine the SWAS Bayesian modelling in the clinical environment. |
| Impact | Jamie Sleigh and I have co-authored 8 papers to date. The collaboration is multi-disciplinary covering the fields of neuroscience and clinical anaesthesia. |
| Start Year | 2014 |
| Description | Collaboration for new B. pertussis vaccine development |
| Organisation | Radboud University Nijmegen Medical Center |
| Country | Netherlands |
| Sector | Academic/University |
| PI Contribution | Base on our experience, we propose a similar program of research into novel vaccine development against another bacterial specie (B. pertussis). WE are bringing the use of viral vector and expertise in preclinical vaccine development |
| Collaborator Contribution | The partner is bringing his expertise in B. pertussis immunology and also a selection of potential antigen targets. |
| Impact | We have established a CDA |
| Start Year | 2019 |
| Description | Collaboration on vaccine development against Coxiella |
| Organisation | Massachusetts General Hospital |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | Expertise in vaccine development against bacterial species, and in preclinical vacinology |
| Collaborator Contribution | The partner designed the project, obtained funding, designed novel antigen targets and leads the scientific development with multiple partners |
| Impact | Too early in the research |
| Start Year | 2018 |
| Description | Collaboration on vaccine development against another Neisseria specie |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Our experience in Neisseria meningitidis vaccine development and in working with a Neisseria specie in the laboratory (design, production, immunogenicity studies in animals and analysis of protective effect, outer membrane production) |
| Collaborator Contribution | The partner Prof. C M designed and conceived a project, secrued funding and led further grant applications. |
| Impact | Grant application to Bactivac, successful Grant application to Welcome trust, result pending |
| Start Year | 2018 |
| Description | Improvement of antigen design |
| Organisation | Children's Hospital Oakland Research Institute (CHORI) |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | Confidential |
| Collaborator Contribution | Confidential |
| Impact | Confidential |
| Start Year | 2014 |
| Description | Industrial collaboration |
| Organisation | Evotec |
| Country | Germany |
| Sector | Private |
| PI Contribution | Supply of new chemical entities |
| Collaborator Contribution | Supply of bioassay and expertise |
| Impact | No finalised outcomes yet |
| Start Year | 2014 |
| Description | Novel bivalent vaccine to prevent both Salmonella Typhi and Paratyphi infections |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We have an expertise in preclinical vaccinology and designed and proposed the project and methodologies. |
| Collaborator Contribution | Our partner has demonstrated that T-cells are induced during acute typhoid and paratyphoid fever in humans against the target antigen that we are proposing (Napolitani et al., manuscript in preparation). The partner will help in characterising the response induced by the vaccine. |
| Impact | The partner provided data that support the project and the grant application. |
| Start Year | 2017 |
| Description | Penlon |
| Organisation | Penlon |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Our collaboration with Penlon and the use of their equipment in our research will be advertised to their local and users of their equipment across the world. We also plan to work with them to ensure compatibility of their MRI machine at 7T. |
| Collaborator Contribution | Penlon have loaned us anaesthetic machine for our research for one year. We are working with them to ensure MRI compatibility of their MRI machine at 7T. |
| Impact | We ahem collected 10 datasets with sevoflurane anaesthesia to date. |
| Start Year | 2018 |
| Description | Preclinical evaluation of a vaccine for Psoriasis |
| Organisation | University of Dundee |
| Department | College of Medicine, Dentistry & Nursing |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Discussion and design of experiments Provision of vaccine and related materials for preclinical studies |
| Collaborator Contribution | Performed experiments - Preclinical studies and analysis of outcomes |
| Impact | Publication of a review article Co-application for further funding Formed a new company - HealVax GmbH, currently seeking investment to fund GMP manufacture and phase I clinical trial. |
| Start Year | 2015 |
| Description | Providing standards |
| Organisation | National Institute for Biological Standards and Control (NIBSC) |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Capacity and running of a clinical trial on meningococcal vaccines |
| Collaborator Contribution | Proposed and support judicious addition to a clinical trial |
| Impact | In progress, multi-disciplinary (immunology, assay development and standardisation) |
| Start Year | 2017 |
| Description | Public health England for YP project |
| Organisation | Public Health England |
| Department | Public Health England Porton Down |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Development of a novel vaccine based on the the expertise developed during this grant. |
| Collaborator Contribution | Capacity to assess the functionality and efficacy of the vaccine candidate |
| Impact | Funding obtained for clinical development of the new vaccine |
| Start Year | 2017 |
| Description | Vector impact on innate T cells |
| Organisation | University of Oxford |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Provide vaccine candidates and models to address fundamental immunology questions |
| Collaborator Contribution | Provide expertise in fundamental immunology of innate T cells in relation to a vaccine modality |
| Impact | In progress |
| Start Year | 2017 |
| Title | BETA LACTAMASE INHIBITORS |
| Description | A compound which is a thienolate of formula (I) or a pharmaceutically acceptable salt thereof: (I) wherein R1, R3, Ring A1, n and Ring A2 are as defined herein, are found to be useful in inhibiting metallo-beta-lactamase and therefore in potentiating the activity of beta lactamase antibiotics. The compound can be used alone or in combination with a rhodanine of formula (II) or a pharmaceutically acceptable salt thereof: (II) wherein R3, Ring A1, n, Ring A2, L and Ring B are as defined herein. Treatment or prevention of bacterial infection in combination with beta-lactam antibiotic agents is also provided. |
| IP Reference | WO2016051133 |
| Protection | Patent application published |
| Year Protection Granted | 2016 |
| Licensed | Commercial In Confidence |
| Impact | Development of beta lactamase inhibitors |
| Title | FUSION POLYPEPTIDES |
| Description | A molecular adjuvant tthat can be incorporated into vectored vaccines |
| IP Reference | EP3535281 |
| Protection | Patent application published |
| Year Protection Granted | 2019 |
| Licensed | No |
| Impact | Not yet |
| Title | FUSION POLYPEPTIDES |
| Description | The present invention relates to fusion polypeptides comprising (a) a 4-oxalocrotonate tautomerase (4-OT)-based polypeptide scaffold which is capable of forming multimers, and (b) a polypeptide antigen; and homo- and hetero-multimers thereof. The invention also provides nucleic acid molecules and vectors encoding the fusion polypeptides and multimers; and methods of using the fusion polypeptides, multimers, nucleic acid molecules and vectors to produce an immunogenic response against the polypeptide antigen. |
| IP Reference | US2019255167 |
| Protection | Patent application published |
| Year Protection Granted | 2019 |
| Licensed | No |
| Impact | none yet |
| Title | FUSION POLYPEPTIDES |
| Description | The present invention relates to fusion polypeptides comprising (a) a 4-oxalocrotonate tautomerase (4-OT)-based polypeptide scaffold which is capable of forming multimers, and (b) a polypeptide antigen; and homo- and hetero-multimers thereof. The invention also provides nucleic acid molecules and vectors encoding the fusion polypeptides and multimers; and methods of using the fusion polypeptides, multimers, nucleic acid molecules and vectors to produce an immunogenic response against the polypeptide antigen. |
| IP Reference | WO2018083475 |
| Protection | Patent application published |
| Year Protection Granted | 2018 |
| Licensed | No |
| Impact | None yet |
| Title | MEDICAL IMAGING |
| Description | The present invention relates to methods of assessing or obtaining an indication of the presence of a cognitive disorder by analysing microstructural changes in regions of the brain. The invention particularly relates to methods of assessing or obtaining an indication of the presence of types of dementia, for example Alzheimer's disease, by analysing changes in minicolumns in regions or layers of the cortex of the brain or of the whole brain. |
| IP Reference | WO2016162682 |
| Protection | Patent application published |
| Year Protection Granted | 2016 |
| Licensed | No |
| Impact | This IP will form a central part of a spin-out company that we expect to form in the next few months. |
| Title | PERCEPTION LOSS DETECTION |
| Description | The present invention relates to a device for detecting a state of true perception loss of a human, the device including processing means operable to detect from information on electrical signals sensed adjacent to the scalp of the human the activity of oscillations present in the electrical signals as a marker for the state of true perception loss of the human. |
| IP Reference | US2015148700 |
| Protection | Patent granted |
| Year Protection Granted | 2015 |
| Licensed | No |
| Impact | In discussion with medical device companies |
| Title | PERCEPTION LOSS DETECTION |
| Description | The present invention relates to a device for detecting a state of true perception loss of a human, the device including processing means operable to detect from information on electrical signals sensed adjacent to the scalp of the human the activity of oscillations present in the electrical signals as a marker for the state of true perception loss of the human. |
| IP Reference | WO2013179048 |
| Protection | Patent granted |
| Year Protection Granted | 2013 |
| Licensed | No |
| Impact | This patent describes the discovery of slow wave activity saturation (SWAS). The Chinese patent was award in March 2018. We have received the final office action from the US Office and are awaiting a response from the EU office. |
| Title | Investigating a new Vaccine against Meningitis B in Oxford (VAMBOX) |
| Description | This is a Phase I/IIa single-site dose-escalation clinical trial to test the safety and immunogenicity of a new vaccine against capsular group B meningococcal disease (MenB). It will be administered alone and following primary immunization with Bexsero, an existing licensed vaccine currently in the UK immunisation schedule for babies. We have started recruiting clinical trial volunteers and are in the process of screening our first participants. |
| Type | Therapeutic Intervention - Vaccines |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2018 |
| Development Status | Under active development/distribution |
| Impact | Work in progress. |
| URL | http://trials.ovg.ox.ac.uk/trials/vambox |
| Title | Novel vaccine against MenB |
| Description | Novel vaccine against MenB, in phase I |
| Type | Preventative Intervention - Physical/Biological risk modification |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2021 |
| Development Status | Actively seeking support |
| Clinical Trial? | Yes |
| Impact | None |
| URL | https://www.isrctn.com/ISRCTN46336916 |
| Title | SWAS depth of ananesthesia monitor |
| Description | We have developed the first prototype of the SWAS depth of anaesthesia monitor and are currently applying this in a pre-surgery clinical trial. |
| Type | Diagnostic Tool - Imaging |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2019 |
| Development Status | Under active development/distribution |
| Impact | refinement and assessment of the prototype is still ongoing as part of the MRC DPFS grant |
| Title | Cortical high intensity profile segmentation for MRI |
| Description | A novel software programme using the FSL platform was developed with collaborators in fMRIB for use in this analysis |
| Type Of Technology | Software |
| Year Produced | 2014 |
| Impact | This software forms part of a patent that has been filed |
| Company Name | Oxford Antibiotics |
| Description | Antibacterial drug discovery |
| Year Established | 2017 |
| Impact | None at this stage (too early), but in active discussion with industry and investors to map future directions |
| Company Name | HealVax GmbH |
| Description | HealVax was spun out from an industrial partner on the Martin Bachmann project funded from CiC 2. It makes vaccines to direct the body to produce its own antibodies, offering an efficient and inexpensive way to treat a number of infectious diseases. |
| Impact | Aiming to use technology to make affordable drugs for the benefit of all |
| Website | https://www.healvax.com/ |
| Company Name | OXFORD BRAIN DIAGNOSTICS LTD |
| Description | The core platform technology, Cortical Disarray Measurement (CDM), has initially been applied to the diagnosis of Alzheimer's disease but has the potential to be used to identify other brain conditions as the company grows and expands into new markets. |
| Year Established | 2018 |
| Impact | Improved diagnosis of Alzheimer's and other brain conditions |
| Description | 'Can we make rabies history?' - Rabies elimination symposium at American Society of Tropical Medicine and Hygiene |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Alexander Douglas (award PI) organised a symposium about rabies control and elimination at the American Society for Tropical Medicine & Hygiene, New Orleans, October 2018, inviting speakers from Scotland, Kenya and Peru. This was attended by around 50 people drawn from diverse backgrounds, with additional attendance via web-streaming / web archive- the meeting audience is broad, including public health practitioners, veterinarians, pharmaceutical industry personnel, non-governmental funders and press, and is the largest international meeting relating to global health. This was the first time a session about rabies has been organised at the meeting for several years- the key aim of the symposium was to raise the profile of rabies as a major public health problem and an important and neglected area for research and policy development. |
| Year(s) Of Engagement Activity | 2018 |
| Description | AIMday Antimicrobial resistance |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | A workshop where businesses proposed their research questions to experts, creating a discussion, brainstorming and generation of novel ideas by academics / other attendees |
| Year(s) Of Engagement Activity | 2019 |
| Description | Alports Syndrome International Workshop (2015) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation to ~150 people attending international workshop on Alports syndrome. Individuals included patients, carers and scientific researchers. Introduced new therapeutic concepts. Wide ranging discussions followed. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Anaesthetic Research Society Committee Member |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Member of the Anaesthetic Research Society Committee that organising national British Journal of Anaesthesia Research Forum conferences on a biannual basis. |
| Year(s) Of Engagement Activity | 2017,2018,2019,2020 |
| Description | Antruk |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Establishement of ANTRUK |
| Year(s) Of Engagement Activity | 2015 |
| URL | http://www.antibioticresearch.org.uk/ |
| Description | Attendee and Speaker at ACCESS conference |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Recent data was presented to the ACCESS group - Anesthesiologists concerned with Cognition, Emergence, Sedation and Sleep - to update the audience on progress made towards understanding brain activity alterations on induction and emergence from general anaesthesia. |
| Year(s) Of Engagement Activity | 2016 |
| Description | BBC Radio 4 broadcast an exploration into this new understanding of psychiatric disorders earlier this year: The Inflamed Mind |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | BBC Radio 4 broadcast an exploration into this new understanding of psychiatric disorders earlier this year: The Inflamed Mind. |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.bbc.co.uk/programmes/b07pj2pw |
| Description | BBC World Service - World Have Your Say - 2017/03/03 |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | BBC World Service Discussion Programme regarding gene therapy in general, specially the use of lentiviral vectors and the correction of sickle cell anaemia. |
| Year(s) Of Engagement Activity | 2017 |
| URL | http://www.bbc.co.uk/programmes/p04tv5n9 |
| Description | Brain Awareness public engagement event |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | A public engagement activities event at the History of Science Museum in Oxford. This was attended by members of the general public. It was free entry and many attendees were international visitors. The public were invited to look through microscopes at histological slides of human brain tissue (all confirmed ethical approval) and discuss what they could see. This was particularly appealing to a group of boys (age 7-11) visiting from Poland. But it also engaged some carers and relatives of people with dementia. In addition, a computer game had been developed by Dr Chance to engage youngsters with the neuroscience of Alzheimer's disease. Playing a fictional character 'shrunk to the size of a cell' the 1 or 2 players descended through the 'cortex' combating mutant tau and avoiding amyloid plaques in order to find stem cells in the sub-ventricular zone and transport them to the hippocampus to rewire into memory circuits. This was played enthusiastically by groups of girls and boys. One little boy's father requested access to the game for his son who returned later in the day in order to complete it. (Unfortunately it was not possible to distrbute the game). |
| Year(s) Of Engagement Activity | 2016 |
| Description | Cafe Scientific Talk (Bradfield College 2015) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Science discussion evenning event at Bradfield College. Wide ranging audience from school children to CF care givers and relatives. Talk stimulated extensive discussion and questions. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Chinese Academy of Sciences |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Postgraduate students |
| Results and Impact | Invited speaker at Chinese Academy of Science, Beijing, 16 May 2018 |
| Year(s) Of Engagement Activity | 2018 |
| Description | Dessimination: Neurosciences Grand Round, John Radcliffe Hospital, Oxford. April 2015 |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Psychiatric channelopathies - Neurosciences Grand Round, John Radcliffe Hospital April 2015 |
| Year(s) Of Engagement Activity | 2015 |
| Description | Global health security (Welcome Trust) |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | to take part in a filming event with the Wellcome Trust. The event is being run/coordinated with Barry Gibb who is a scientific multimedia producer for the WT. The event is centred around a computer game called The Last of Us. The game is based on a pandemic which has infected 60% of humanity in several months. They would like our input for a 'vaccine' discussion. The game will be used as the fiction starting point for discussion. |
| Year(s) Of Engagement Activity | 2016 |
| URL | https://mosaicscience.com/outbreak |
| Description | Guest Speaker at Genome Editing conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Highlighting Viral and Non-Viral Gene Therapy for Cystic Fibrosis |
| Year(s) Of Engagement Activity | 2017 |
| Description | Guest speaker at CF Conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation to conference on Emerging gene therapies for cystic fibrosis' |
| Year(s) Of Engagement Activity | 2017 |
| Description | Guest speaker at CFF Research Conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Made a presentation on Sendai Virus Pseudotyped Lentiviral Vectors to conference members |
| Year(s) Of Engagement Activity | 2017 |
| Description | Immunisation Seminar |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation of the project and its status to nurses attending the yearly Immunisation Seminar organized by the oxford Vaccine Group |
| Year(s) Of Engagement Activity | 2017 |
| Description | Invited seminar at Oxford Centre for Human Brain Activity |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | Discussion of the current understanding of the effects of anaesthesia on brain function. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Invited talk for the Translationnal Reserach Office |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Other audiences |
| Results and Impact | A information meeting / workshop to provide information to research scientists on translational funding schemes (application, difficulties, further funding) |
| Year(s) Of Engagement Activity | 2019 |
| Description | Keynote address, Encephalitis Society Professional Seminar 2015, London |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Keynote address: What do psychiatrists have to offer in the management of Augoimmune Encephalitis |
| Year(s) Of Engagement Activity | 2015 |
| URL | http://www.encephalitis.info/files/2714/4596/2037/Prof_seminar_2015_WEB.pdf |
| Description | Member of Thames Valley Perioperative Medicine Partnership |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Member of Thames Valley Perioperative Medicine Partnership that aims to encourage perioperative research throughout the region. |
| Year(s) Of Engagement Activity | 2018,2019 |
| Description | OMCAN |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | Committee member of the Oxford Mathematics of Consciousness Applications Network is a University of Oxford network to encourage collaborations in the field of consciousness research |
| Year(s) Of Engagement Activity | 2018,2019 |
| Description | Oxford Sciences Innovation Life Sciences Event |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation of MRC CiC funded project on Slow wave activity saturation (SWAS) as a marker of depth of anaesthesia at local event for previous awardees and future applicants. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Oxford University Hospitals NHS Foundation Trust Audit Meeting |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | I gave the University lecture at the Nuffield Department of Anaesthesia Audit on "Anaesthesia and Brain Function" to the practising anaesthetists within the local NHS Trust. It was described as the "most clinically relevant lecture in years" and "potentially ground breaking" research. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Participation in a television programme on BBC Two - Trust Me, I'm a Doctor. A special programme focussing on Mental Health |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | In the relevant section of the TV programme - "Could some mental health conditions be caused by an immune malfunction" I explained that some patients who exhibit classic symptoms of psychosis may not actually have a psychiatric condition, but a rare form of encephalitis and that the biological cause for this condition is now increasingly recognized by psychiatrists and neurosurgeons. Patients have been successfully treated with immunotherapy, which removes the rogue antibodies from the patient's blood. This treatment has led to patients making a dramatic recovery. I also described my current research investigating the prevalence of pathogenic antibodies in psychosis and its subsequent treatment. This was followed by a large number of enquiries from members of the public both nationally and internationally. |
| Year(s) Of Engagement Activity | 2017 |
| URL | http://www.bbc.co.uk/programmes/articles/4dbMnJVnLBM9Qqp8rzKD4s3/could-some-mental-health-conditions... |
| Description | Peking University, Beijing |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited talk at Peking University, Beijing |
| Year(s) Of Engagement Activity | 2018 |
| Description | Presentation and Cambridge Neuroscience Seminar 2017 - The Inflamed Brain - 21 March |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Plenary "The Autoimmune basis of Psychosis - challenges and controversies |
| Year(s) Of Engagement Activity | 2017 |
| URL | http://www.neuroscience.cam.ac.uk/events/event.php?permalink=dbbbdfb739#plenary |
| Description | Presentation at British Journal of Anaesthesia Research Forum |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presented outcome of work completed on award to anaesthetists - potential end users. It was observed to be a big step towards individualised depth of anaesthesia monitoring. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Presentation at the 6th European Conference on Schizophrenia Research (ECSR) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Symposium presentation entitled: "The diagnosis and management of autoimmune encephalitis in psychiatric settings" at the 6th European Conference on Schizophrenia Research (ECSR), 24/11/2016 |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.cpo-media.net/DGPPN/2016/Programm/HTML/files/assets/common/downloads/publication.pdf |
| Description | Presentation to Rethink Mental Illness charity, Harrogate May 2015 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Presentation to Rethink Mental Illness charity in Harrogate, May 2015. Title: Brains on Fire. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Presentation to Urgent Care Research Conference |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Targeted clinicians and researchers involved with NIHR Clinical Research Network Thames Valley and South Midlands |
| Year(s) Of Engagement Activity | 2016 |
| Description | Presentation: The prevalence of antibodies against neuronal cell surface targets in acute first episode psychosis, 15th International Congress on Schizophrenia Research' in Colorado Springs, Colorado, USA |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | This was a plenary session attended by academics and clinicians. Members of the audience remarked they were more convinced by the research presented in this session than had been heard previously. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Presentations to psychiatric teams: January - Reading, February - Oxford, March - Buckinghamshire, May - Swindon, June - Chippenham |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Antibodies and psychosis - what psychiatrists need to know - presentations to psychiatric teams: Reading Jan 2015, Oxford Feb 2015, Buckinghamshire March 2015, Swindon May 2015, Chippenham June 2015 |
| Year(s) Of Engagement Activity | 2015 |
| Description | Public Lecture |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | Yes |
| Geographic Reach | Regional |
| Primary Audience | Schools |
| Results and Impact | Lecture initiated questions on working in STEM subjects Considerable interest from talented students to pursue career in research, particularly Oxford |
| Year(s) Of Engagement Activity | 2014 |
| Description | Research Meeting, MRC HQ London |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Meeting of potential investigators (psychiatrists and neurologists) to set up a network across England to seek out people with antibody-mediated psychosis and then offer them the change to be in a randomised controlled trial, to test the pathogenicity of these antibodies, using IVIG and rituximab. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Romney Street Group |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Presentation and debate with the Romney Street Group, |
| Year(s) Of Engagement Activity | 2020 |
| Description | School visit (St gabriels) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Schools |
| Results and Impact | A lecture at a secondary school, intended for years 13 and above (A levels). The intended purpose was to engage / teach about vaccines and how they work, how they are developped, and what is the typical job /career of a research scientist |
| Year(s) Of Engagement Activity | 2019 |
| Description | Symposium speaker at British Neuroscience Association Festival of Neuroscience 2015 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation detailing how brain activity in altered physiological states such as anaesthesia and pain could be quantified using functional imaging to an audience of ~100 UK neuroscientists. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Teaching/Science Session: Channelopathies: An open and shut case? Psychiatric channelopathies at Association of British Neurologists Annual Meeting, Harrogate |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Teaching/Science Session: Channelopathies: An open and shut case? Psychiatric channelopathies |
| Year(s) Of Engagement Activity | 2015 |
| URL | http://www.theabn.org/media/docs/Meetings/2015%20ABN%20Harrogate%20draft%20programme_28.pdf |
| Description | UNIQ |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Schools |
| Results and Impact | I lead the UNIQ Spring and Summer schools program for potential Medicine, Biomedical Science and Psychology students at the University of Oxford on behalf of the Wellcome Centre for Integrative Neuroimaging. I organise neuroimaging-based demonstrations and give lectures that are tailored for each subject area. I typically run 3-4 sessions a year, reaching 100-120 sixth-form students. |
| Year(s) Of Engagement Activity | 2016,2017,2018,2019,2020 |